-
Published on Sep 23, 2016
Shares
of Corbus Pharmaceuticals (CRBP) have raced 325% higher in 2016 due to its
Resunab drug which received "Fast Track" designation by the Food and
Drug Administration. The company's CEO Dr. Yuval Cohen does not expect
things to slow down anytime soon.
www.corbuspharma.com/
www.corbuspharma.com/
Dr. Mayes and Dr. Chmiel share their opinion on why now is an exciting time for #CF and #systemicsclerosis patients https://t.co/vXWPcEcqyQ— Corbus Pharma (@CorbusPharma) September 22, 2016
No comments:
Post a Comment